ANIK Anika Therapeutics, Inc.
USHealthcareAs of 2026-07-10 16:00
Why ANIK matters now
Anika Therapeutics, Inc. (ANIK) is a US stock in Healthcare. The latest InvestLog snapshot shows $15.60 with -3.05% on the session and $207.6M in market capitalization; recent performance reads 1-month -2.70% and YTD +50.05%.
The latest financial table shown here is Q1 2026, with revenue of $29.6M, net income of $-5.1M, and EPS of $-0.37. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield 0.5%.
The latest indexable market news headline is "Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)" from GlobeNewsWire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $—; recent insider activity includes Griffin Stephen D. filing M-Exempt. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
1.46
P/S
1.65
EV/EBITDA
-38.11
DCF Value
$0.44
FCF Yield
0.5%
Div Yield
0.0%
Margins & Returns
Gross Margin
58.6%
Operating Margin
-10.5%
Net Margin
-9.5%
ROE
-7.7%
ROA
-6.2%
ROIC
-7.6%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $29.6M | $-5.1M | $-0.37 |
| Q4 2025 | $30.6M | $292.0K | $0.02 |
| FY 2025 | $112.8M | $-10.9M | $-0.76 |
| Q3 2025 | $27.8M | $-2.3M | $-0.16 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$—
Target (Median)
$—
Target Range
$— - $—
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Medical - Devices
Country
US
Exchange
—
Beta
0.23
Anika Therapeutics, Inc. is a company dedicated to joint preservation, innovating and providing early intervention orthopedic care across the globe, including the United States and Europe. Their core focus areas include osteoarthritis (OA) pain management, regenerative solutions, soft tissue repair, and advanced bone-preserving joint technologies. All of Anika's products are developed, manufactured, and commercialized utilizing their proprietary hyaluronic acid (HA) technology platform. Their comprehensive product lines feature an OA pain management family, which includes established treatments like Monovisc, Orthovisc, Cingal, and Hyvisc, all designed to alleviate discomfort from osteoarthritis. The company's joint preservation and restoration offerings are extensive, comprising approximately 150 bone-sparing joint technology products, alongside solutions for sports medicine soft tissue repair and orthopedic regenerative therapies. Furthermore, Anika leverages its HA expertise in a non-orthopedic product family, developing applications such as adhesion barriers, advanced wound care products, ophthalmic solutions, and ear, nose, and throat treatments. Anika Therapeutics, Inc. was established in 1983 and is based in Bedford, Massachusetts.